心肌保护
传出细胞增多
医学
心肌梗塞
封锁
药理学
纳米医学
微泡
心功能曲线
心脏病学
外体
血小板
内生
心力衰竭
胞外囊泡
纤维化
药物输送
调节器
内科学
作者
Qi Pan,Ye Zhu,Ziqin Zhou,Yao Jiang,Yuejin Yang,Ling Yu,Yuanwei Pan,Guihao Chen
摘要
Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.
科研通智能强力驱动
Strongly Powered by AbleSci AI